412 related articles for article (PubMed ID: 29901705)
1. Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study).
Miyamoto K; Fukuhara N; Maruyama D; Shibata T; Nakamura K; Ishizawa K; Tsukasaki K; Nagai H;
Jpn J Clin Oncol; 2018 Aug; 48(8):777-780. PubMed ID: 29901705
[TBL] [Abstract][Full Text] [Related]
2. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Ardeshna KM; Qian W; Smith P; Braganca N; Lowry L; Patrick P; Warden J; Stevens L; Pocock CF; Miall F; Cunningham D; Davies J; Jack A; Stephens R; Walewski J; Ferhanoglu B; Bradstock K; Linch DC
Lancet Oncol; 2014 Apr; 15(4):424-35. PubMed ID: 24602760
[TBL] [Abstract][Full Text] [Related]
3. Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.
Reagan PM; Friedberg JW
Curr Treat Options Oncol; 2015 Jul; 16(7):32. PubMed ID: 26031546
[TBL] [Abstract][Full Text] [Related]
4. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.
Jurczak W; Moreira I; Kanakasetty GB; Munhoz E; Echeveste MA; Giri P; Castro N; Pereira J; Akria L; Alexeev S; Osmanov E; Zhu P; Alexandrova S; Zubel A; Harlin O; Amersdorffer J
Lancet Haematol; 2017 Aug; 4(8):e350-e361. PubMed ID: 28712941
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
Ogura M; Sancho JM; Cho SG; Nakazawa H; Suzumiya J; Tumyan G; Kim JS; Lennard A; Mariz J; Ilyin N; Jurczak W; Lopez Martinez A; Samoilova O; Zhavrid E; Yañez Ruiz E; Trneny M; Popplewell L; Coiffier B; Buske C; Kim WS; Lee SJ; Lee SY; Bae YJ; Kwak LW
Lancet Haematol; 2018 Nov; 5(11):e543-e553. PubMed ID: 30389036
[TBL] [Abstract][Full Text] [Related]
6. Rituximab maintenance therapy for follicular lymphoma: no better than watchful waiting.
Prescrire Int; 2012 Mar; 21(125):62. PubMed ID: 22428182
[TBL] [Abstract][Full Text] [Related]
7. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Zhou X; Taylor M; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
Br J Haematol; 2016 Mar; 172(5):724-34. PubMed ID: 26729445
[TBL] [Abstract][Full Text] [Related]
8. Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden.
Fukuhara N; Ishizawa K
Jpn J Clin Oncol; 2019 Apr; 49(4):306-310. PubMed ID: 30715424
[TBL] [Abstract][Full Text] [Related]
9. [Low grade lymphoma: research progress and questions about treatment].
Ishizawa K
Rinsho Ketsueki; 2015 Oct; 56(10):2039-46. PubMed ID: 26458443
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).
Schneider T; Rosta A; Losonczy H; Radványi G; Ujj G; Egyed M; Illés Á; Jakucs J; Szerafin L; Gasztonyi Z; Masszi T; Iványi J; Demeter J; Dombi P; Tóth A; Borbényi Z
Pathol Oncol Res; 2018 Apr; 24(2):199-205. PubMed ID: 28432650
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.
Kim WS; Buske C; Ogura M; Jurczak W; Sancho JM; Zhavrid E; Kim JS; Hernández-Rivas JÁ; Prokharau A; Vasilica M; Nagarkar R; Osmanov D; Kwak LW; Lee SJ; Lee SY; Bae YJ; Coiffier B
Lancet Haematol; 2017 Aug; 4(8):e362-e373. PubMed ID: 28712940
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.
Davies A; Merli F; Mihaljević B; Mercadal S; Siritanaratkul N; Solal-Céligny P; Boehnke A; Berge C; Genevray M; Zharkov A; Dixon M; Brewster M; Barrett M; MacDonald D
Lancet Haematol; 2017 Jun; 4(6):e272-e282. PubMed ID: 28476440
[TBL] [Abstract][Full Text] [Related]
13. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
14. The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma.
Davies GA; Ghosh S; Oh DH; Manna M; Peters AC; Stewart CA; Stewart DA
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):829-835. PubMed ID: 30243571
[TBL] [Abstract][Full Text] [Related]
15. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
[TBL] [Abstract][Full Text] [Related]
18. A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
Eba J; Shimokawa T; Nakamura K; Shibata T; Misumi Y; Okamoto H; Yamamoto N; Ohe Y;
Jpn J Clin Oncol; 2015 Jan; 45(1):115-8. PubMed ID: 25332420
[TBL] [Abstract][Full Text] [Related]
19. The role of "watch and wait" in intestinal follicular lymphoma in rituximab era.
Tari A; Asaoku H; Takata K; Fujimori S; Tanaka S; Fujihara M; Koga T; Yoshino T
Scand J Gastroenterol; 2016 Mar; 51(3):321-8. PubMed ID: 26382560
[TBL] [Abstract][Full Text] [Related]
20. The outcome of watchful waiting in patients with previously treated follicular lymphoma.
Fujino T; Maruyama D; Maeshima AM; Saito Y; Ida H; Hosoba R; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Kuroda J; Izutsu K
Cancer Med; 2022 May; 11(10):2106-2116. PubMed ID: 35129305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
